Harvard Bioscience (HBIO) Current Deferred Revenue (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Current Deferred Revenue data on file, last reported at $3.7 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 1.16% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $3.7 million, a 1.16% decrease from a year earlier, with the FY2025 full-year figure at $3.6 million, down 4.23% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $3.7 million, up from $3.6 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for HBIO reached as high as $4.5 million in Q4 2023 and fell as low as $3.1 million in Q2 2025.
• Historically, Current Deferred Revenue has averaged $3.8 million across 5 years, with a median of $3.7 million in 2025.
• Across the five-year window, Current Deferred Revenue soared 33.77% in 2023 and retreated 21.62% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $3.4 million in 2022, then soared by 33.77% to $4.5 million in 2023, then fell by 15.57% to $3.8 million in 2024, then slipped by 4.23% to $3.6 million in 2025, then advanced by 0.58% to $3.7 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $3.7 million in Q1 2026, $3.6 million in Q4 2025, and $3.2 million in Q3 2025.